Onco Actu du 1er février 2016

	1. Biologie
How predictable is cancer? [The Institute of Cancer Research] “It’s similar to forecasting the weather – it took meteorologists a long time to work out what they should measure and how to measure it to make reliable predictions. And they accept that there are imperfections which are hard to overcome. “
	3. Prévention
Fruit and veg 'could reduce breast cancer risk by one quarter' [The Telkegraph] The study - which tracked 90,000 US women for more than two decades - found fibre from fruit and vegetables appeared to have the strongest protective effect.
Don't risk skin cancer while chasing vitamin D boost, authorities warn [The Guardian] Australian authorities have released new advice on prolonged sun exposure amid concerns people are risking skin cancer in the mistaken belief they are boosting their vitamin D levels.
	3.3 Prévention - Vaccins
Sixty-Nine Cancer Centers Urge HPV Vaccination [The Cancer Letter] In an unprecedented move, 69 NCI-designated cancer centers have come together to advocate for HPV vaccination as a preventive measure against many HPV-related cancers.
	4.10 Dép., diag. & prono. - FDA, EMA, NICE,...
Glossary - BEST (Biomarkers, EndpointS, and other Tools) Resource [NCBI Bookshelf] FDA-NIH Biomarker Working Group.
	4.12 Biopsies liquides
Avera Medical Group and Epic Sciences collaborate on cancer precision medicine clinical trials [Epic Sciences] Following a simple blood draw, the Epic Sciences technology can detect all categories of CTCs in the blood and identify, on a single cell basis, subpopulations of metastatic cancer cells that may be resistant or susceptible to cancer therapies.
	4.9 Dép., diag. & prono. - Sein
DNA in healthy breast tissue may indicate cancer risk [UPI] "These new data show how epigenetic alterations, if detected early enough, could be used to identify women at higher risk of developing breast cancer."
	5. Traitements
Proton beam therapy has fewer harsh side effects, according to child cancer study [The Guardian] “Proton radiotherapy resulted in acceptable toxicity and had similar survival outcomes to those noted with conventional radiotherapy, suggesting that the use of the treatment may be an alternative to photon-based treatments.”
Proton beam cancer therapy 'effective with fewer side effects' [BBC News] Researchers looked at 59 patients aged between three and 21 from 2003 to 2009.
A Conversation about Cancer Nanotechnology [National Cancer Institute] NCI recently released the Cancer Nanotechnology Plan 2015. In this interview, Piotr Grodzinski, Ph.D., director of NCI’s Office of Cancer Nanotechnology Research, discusses the 2015 plan as well as new developments in nanotechnology-based therapeutics and diagnostics and the clinical opportunities being generated by the nanotechnology field.
	5.12 Immunothérapies
The synNotch solution: UCSF scientists engineer a next-gen T-cell immunotherapy [FierceBiotech Research] In a project described in Cell, the team says they created a synNotch that recognized an antigen on the surface of the cancer cell while the internal mechanism contributed a chimeric antigen receptor that recognized a different antigen.
Synthetic biologists aim for better cancer-fighting cells [STAT] More than any potential use in cancer treatment, however, the studies suggest that it’s possible to engineer a customized switch into a cell — able to recognize any molecule in the body and turn on any genes in response.
	5.3 Traitements - FDA, EMA,...
Orphan Medicines in the EU: A 15-Year Review [RAPS] About a third of all orphan applications deal with some form of cancer, and the most frequently designated rare conditions include acute myeloid leukemia, cystic fibrosis, glioma, pancreatic carcinoma ovarian cancer, multiple myeloma, chronic lymphoblastic leukemia and hepatocellular carcinoma.
	5.3.4 Traitements - AMM (FDA, EMA)
Exelixis Announces European Medicines Agency Acceptance of Marketing Authorization Application for Cabozantinib as a Treatment for Advanced Renal Cell Carcinoma [Exelixis] he MAA is based on the results of METEOR, a phase 3 pivotal trial comparing cabozantinib to everolimus in patients with advanced RCC who experienced disease progression following treatment with a VEGF receptor tyrosine kinase inhibitor.
EMA fast-tracks treatment of multiple myeloma for approval in EU [EMA] It is to be used in combination with lenalidomide and the anti-inflammatory medicine dexamethasone for the treatment of patients who have received at least one prior therapy.
Exelixis Announces U.S. FDA Deems New Drug Application Sufficiently Complete and Grants Priority Review for Cabozantinib as a Treatment for Advanced Renal Cell Carcinoma [Exelixis] The NDA will be considered officially filed 60 days from the date of the completion of the submission, or February 20, 2016.
Bristol-Myers Squibb and AbbVie Receive Positive CHMP Opinion for Investigational Antibody, Empliciti (elotuzumab), for the Treatment of Multiple Myeloma in Patients Who Have Received at Least One Prior Therapy [BMS] Positive opinion based on reduction in the risk of disease progression or death with Empliciti in combination with standard of care regimen for multiple myeloma demonstrated in ELOQUENT-2 study.
	6. Lutte contre les cancers
Drug Shortages Forcing Hard Decisions on Rationing Treatments [NY Times] An international group of pediatric cancer specialists was so troubled about the profession’s unsystematic approach to distributing scarce medicine that it developed rationing guidelines that are being released Friday in The Journal of the National Cancer Institute.
Germany’s excellence program gets good grades [Science] Since 2006, the federal government has poured €4.6 billion into the Excellence Initiative, an effort to reshape the country’s publicly funded universities.
An ethical way to choose which kids get chemo during a shortage? [Reuters] There are about 265 drugs currently in short supply in the U.S., down from a peak of 320 as of September 2014.
	6.10 Politiques
Precision Medicine: A One-Year Update [Medium] By DJ Patil, Chief Data Scientist in the White House Office of Science and Technology Policy, and Stephanie Devaney, Project Manager of the Precision Medicine Initiative.
Biden’s cancer bid exposes rift among researchers [Politico] The debate, which revolves around how fast researchers should have to share results from government-funded clinical trials, aired biomedicine’s dirty laundry in public.
Big Pharma takes a beating on the Democrats' campaign trail [STAT] “They are getting away with murder,” Sanders said, “and in some cases they are committing murder.” The audience applauded approvingly.
Obama's 'Cancer Moonshot' Should Start With The Basics [Fortune] Many research scientists, physicians, and advocates will advise the Vice President that what we need most in the fight against cancer is more research funding. And additional funding would help for sure. But even more than that, we need roads.
	6.11 Patients
Why are doctors so bad at telling patients they’re dying? [STAT] Dr. Janet Abrahm was in a hospital cafeteria when she heard the oncologist and his patient nearby. “Your husband isn’t here?” he said. “OK, well, let me tell you anyway. Your leukemia has returned.”
Video Helps Prepare Patients to Participate in Cancer Trials [National Cancer Institute] Patients in the study who took part in a tailored, video-based educational program had a better understanding of clinical trials and fewer concerns about issues such asrandomization and side effects than patients who received text-based educational materials, the study authors reported.
	6.7 DMP, Big Data & applis
ASCO Encouraging Members to Have Their Practices Become CancerLinQ Early Adopters [ASCO] Practices who sign up before June 1, 2016, will receive numerous benefits.
	6.9 Controverses
Texas Cancer Agency Names James Willson Top Science Officer [Xconomy] While Willson’s new role comes with a focus on boosting academic research, he says he plans to work with the agency’s commercialization staff to help translate that research into viable therapies.